ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: 1856

Abnormal DNA Methylation in CD4+T Cells Is Associated with Cardiovascular Risk in Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1530

Activin a and Follistatin Alter Endothelial Cell and Rheumatoid Arthritis Synovial Fibroblast Adhesion and Interaction

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1576

Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1593

Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus: Results of a Quality Improvement Initiative

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1706

Advanced Integrated Science Courses: A Novel Approach to Medical Student Science Education

Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1830

Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1838

Aerobic Exercise Improves Fatigue and Quality of Life in Women with Systemic Lupus Erythematosus (Preliminary Analysis)

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1819

Altered Brain Functional Connectivity in Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1836

Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1545

An Artificial Intelligence (AI) Assistant Identifying Spinal Diffuse Idiopathic Skeletal Hyperostosis on Plain X-rays: A Pilot Deep Learning Study

Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Abstract Number: 1801

An Engineered Extracellular Matrix‐rich Decellularized Substrate Based Podocytes Culture System to Study Intracellular Complement Production and Activation

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1589

An Initiative to Improve Timely Glucocorticoid Tapering in Vasculitis

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1860

An Integrative Approach to Identify Heritable and De Novo Genomic Variations in Psoriatic Arthritis Mutilans and Understand Its Systems Biology

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1725

An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1647

An Oleuropein-based Dietary Supplement Improves Joint Function in Older People with High Knee Joint Pain

Osteoarthritis – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].